2025-01-01 2025-12-31 false No description of principal activity Capium Accounts Production 1.1 14553431 2025-01-01 2025-12-31 14553431 bus:AbridgedAccounts 2025-01-01 2025-12-31 14553431 bus:Micro-entities 2025-01-01 2025-12-31 14553431 bus:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 14553431 bus:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 14553431 bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 14553431 2025-01-01 2025-12-31 14553431 2025-12-31 14553431 bus:RegisteredOffice 2025-01-01 2025-12-31 14553431 core:WithinOneYear 2025-12-31 14553431 core:AfterOneYear 2025-12-31 14553431 1 2025-01-01 2025-12-31 14553431 bus:Director1 2025-01-01 2025-12-31 14553431 bus:Director1 2025-12-31 14553431 bus:Director1 2024-01-01 2024-12-31 14553431 2024-01-01 14553431 bus:LeadAgentIfApplicable 2025-01-01 2025-12-31 14553431 2024-01-01 2024-12-31 14553431 2024-12-31 14553431 core:WithinOneYear 2024-12-31 14553431 core:AfterOneYear 2024-12-31 14553431 bus:EntityAccountantsOrAuditors 2024-01-01 2024-12-31 14553431 bus:OrdinaryShareClass1 2025-01-01 2025-12-31 14553431 bus:OrdinaryShareClass1 2025-12-31 14553431 bus:OrdinaryShareClass1 2024-01-01 2024-12-31 14553431 bus:OrdinaryShareClass1 2024-12-31 14553431 core:CostValuation core:Non-currentFinancialInstruments 2025-12-31 14553431 core:CostValuation core:Non-currentFinancialInstruments 2024-12-31 14553431 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2025-12-31 14553431 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2025-12-31 14553431 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-12-31 14553431 core:Non-currentFinancialInstruments 2025-12-31 14553431 core:Non-currentFinancialInstruments 2024-12-31 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 14553431
England and Wales

 

 

 

V DRUG LIMITED


Abridged Accounts
 


Period of accounts

Start date: 01 January 2025

End date: 31 December 2025
  2025   2024
    £ £   £ £
Called up share capital not paid   1      1 
Current assets 23,025      20,043   
Prepayments and accrued income (1)     (1)  
Creditors: amount falling due within one year 1,958      (2,066)  
Net current assets   24,982      17,976 
Total assets less current liabilities   24,983      17,977 
Net assets   24,983      17,977 
 

         
Capital and reserves   24,983      17,977 
 
NOTES TO THE ACCOUNTS

General Information
V DRUG LIMITED is a private company, limited by shares, registered in England and Wales, registration number 14553431, registration address 8 BAZLEY CLOSE, SWANSCOMBE UNITED KINGDOM, DA10 0FF.

The presentation currency is £ sterling.
1.

Accounting policies

Significant accounting policies
Statement of compliance
These financial statements have been prepared in compliance with FRS 105 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.
Basis of preparation
The financial statements have been prepared under the historical cost convention.
The financial statements are prepared in sterling which is the functional currency of the company.
2.

Average number of employees

Average number of employees during the year was 3 (2024 : 0).


For the year ended 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:
The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.

The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the micro-entity provisions and FRS 105, the Financial Reporting Standard applicable to the micro-entities regime. The accounts have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. The income statement has not been delivered to the Registrar of Companies.

The members have agreed to the preparation of abridged accounts.
The financial statements were approved by the director on 17 September 2026 and were signed by:


--------------------------------
Viorel DRUG
Director
1